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Abstract
Purpose Adverse drug reactions as well as vitamin D defi-
ciency are issues of public health concern in older people.
However, relatively little is known about the impact of drug
use on vitamin D status. Our primary aim is to explore asso-
ciations between drug use and vitamin D status in older peo-
ple. Furthermore, prevalences of drug use and vitamin D de-
ficiency are estimated.
Methods In a population of 873 community-dwelling Dutch
geriatric outpatients, we explored the cross-sectional relation-
ships of polypharmacy (≥5 medications concomitantly used),
severe polypharmacy (≥10 medications), and use of twenty-
one specific drug groups, with serum 25-hydroxyvitamin D
(25(OH)D) by analysis of covariance.
Results Overall prevalence of polypharmacy was 65 %, of
severe polypharmacy 22 %. Depending on the cut-off value,
prevalence of vitamin D deficiency was 49 % (<50 nmol/l) or
77 % (<75 nmol/l). Of the patients using a vitamin D supple-
ment, 17 % (<50 nmol/l) or 49 % (<75 nmol/l) were still
deficient. In non-users of supplemental vitamin D, after ad-
justment for age and gender, negative associations were found
for severe polypharmacy, metformin, sulphonamides and urea
derivatives (SUDs), vitamin K antagonists, cardiac glyco-
sides, loop diuretics, potassium-sparing diuretics, ACE inhib-
itors, and serotonin reuptake inhibitors; for non-selective
monoamine reuptake inhibitors (NSMRIs) the association
was positive. The most extreme impacts of drug use on ad-
justed mean 25(OH)D were −19 nmol/l for SUDs and
+18 nmol/l for NSMRIs.
Conclusion Drug use should be considered a risk factor for
vitamin D deficiency amongst geriatric outpatients.
Keywords Adverse drug reaction . Drug-food interaction .
VitaminD . Polypharmacy . Elderly
Introduction
Adverse drug reactions (ADRs) substantially contribute to
global disease burden. Median prevalence of ADR-related
hospital admissions in European countries is estimated
3.5 %, prevalence of ADRs amongst inpatients 10.1 % [1].
These figures increase significantly with increase in age [2].
The high prevalence of vitamin D deficiency in older
people is also an issue of global public health concern
[3]. Apart from a negative impact on calcium metabo-
lism and bone health, vitamin D deficiency might also
lead to non-skeletal diseases and an increased inflamma-
tory status: [4, 5]. An important determinant of
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deficiency of this micronutrient is a reduced synthesis
of precursors in the skin by increase in age, less expo-
sure to sunlight, or pigmented skin. Furthermore, insuf-
ficient dietary intake, impaired absorption, liver or kid-
ney dysfunction, obesity, and inflammation may be of
influence [6–10]. However, about the role of medication
little is known. Observational and experimental research
on this subject is scarce [11]. Also during drug devel-
opment and in post-marketing studies, drug effects on
nutritional status are not specifically addressed [12].
This is remarkable, as drug use as well as an impaired
nutritional status are related to frailty [13–15] and pre-
dict disability, hospitalisations, and death [16].
Challenged by the lack of knowledge of this type of
adverse drug reaction, we formulated the following
study objectives: to investigate cross-sectional relation-
ships of polypharmacy, number of drugs used, and use
of 21 individual drug groups with serum 25-
hydroxyvitamin D (25(OH)D); secondary aims were to
determine prevalences of drug use and vitamin D defi-
ciency. For statistical analyses we used data from a
population of community-dwelling geriatric outpatients
of a Dutch, non-academic, regional hospital.
Methods
Study population
Our original study population consisted of 892
community-living outpatients of the department of
Geriatric Medicine of Gelderse Vallei Hospital (Ede,
The Netherlands) at their first visit of the outpatient
c l inic , f rom August 2011 unt i l January 2013.
Indications for consultation were cognitive problems
(60 %), falls (14 %) or other (24 %). Patient data were
registered in the electronic patient file system Norma
EPD. After exclusion of subjects either younger than
55 years or not having 25(OH)D measured, data of
783 patients were left for initial analysis. In a subgroup
of 631 patients not using a vitamin D supplement, as-
sociations between drug use and serum vitamin D were
explored in a simple regression model. Because of miss-
ing data, another 29 subjects were omitted in the com-
plex model (N= 602). According to the Dutch Medical
Research Involving Human Subjects Act (WMO) no
ethical approval was needed, since this study involved
retrospective analysis of anonymised patient data only.
Data
History, physical examination and other clinical assess-
ments of the geriatric patients were conducted by the
medical staff, assisted by trained nurses. Non-fasting
blood samples were collected at the Gelderse Vallei
Hospital on the day of first visit. Assays were conduct-
ed by the hospital laboratory once a week. Vitamin D
status was measured using the 25-OH-Vitamin D3/D2
Reagent Kit for HPLC analysis according to the manu-
facturer’s instructions (Chromsystems Instruments &
Chemicals, Gräfelfing, Germany). For more details on
25(OH)D assessment we refer to the electronic supple-
mentary material. Standardised anthropometric measure-
ments were conducted by trained nurses. Weight was
determined to the nearest 0.1 kg through a digital floor
scale (Seca 770), height to the nearest 0.1 cm using a
telescopic height rod (Seca 220). If patients had diffi-
culties with standing, only weight was measured using a
chair scale (Seca D94-09-033). Assessment of drug use
was based on both prescribed and over-the-counter
drugs the patients were asked to bring to the clinic,
on (hetero)anamnesis, and on medication lists from
pharmacies, if available. Non-compliance was structural-
ly asked for. The Mini Nutritional Assessment (MNA)
was performed in patients aged 65 and older. Collected
patient data were registered in the hospital electronic
patient file system Norma/NeoZis according to hospital
standards.
Raw patient data were extracted from the patient files and
further processed. The day of blood collection was recorded
into the variable season: winter (October–March) or summer
(April–September). Education attainment was classified
as either primary school (≤6 years) or post-primary ed-
ucation and higher (>6 years), smoking as never, ever,
and current. Categorisation of alcohol use was based on
the Alcohol Consumption Index according to Garretsen:
not/light, moderate, excessive/very excessive [17].
Medication and supplements were coded by the
Anatomic Therapeutical Classification (ATC) index.
Polypharmacy was defined as the concomitant use of
five or more different ATC-coded substances; severe
polypharmacy for ten or more. Medications of interest
were drug groups at ATC level 4 used by minimally
10 % of the patients: proton pump inhibitors (PPIs), os-
motically active laxatives, biguanides, sulfonamides and urea
derivatives (SUDs), vitamin K antagonists, platelet aggrega-
tion inhibitors, thiazide diuretics, loop diuretics, selective be-
ta-blocking agents, dihydropyridines, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin-2 antagonists, statins,
anilides, non-selective monoamine reuptake inhibitors
(NSMRIs), and selective serotonin reuptake inhibitors
(SSRIs). For a more complete comparison with the results of
a similar cross-sectional study, also cardiac glycosides, ben-
zodiazepines, oral antidiabetics, potassium-sparing di-
uretics, and antidepressants were investigated [18].
After being processed, data were ready to be analysed.
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Statistical analysis
Statistical analyses were conducted with IBM SPSS sta-
tistics Version 20. Because of non-normal distributions,
numerical data were reported as medians with interquar-
tile range (IQR); categorical data as prevalences.
Medians were compared by the nonparametric median
test, differences between prevalences by chi-squared
tests. Analysis of covariance (ANCOVA) was applied
to investigate the associations between the dependent
variable 25(OH)D, and the independent variables ‘num-
ber of ATC-coded substances’, polypharmacy, severe
polypharmacy, and twenty-one individual drug groups
in subjects not taking a specific vitamin D supplement.
Use of medication was compared to non-use.
Two regression models were constructed for each
drug group in non-users of supplemental vitamin D.
Firstly, a simple regression model with age and gender
as confounders, and secondly, a complex model that
also adjusts for BMI, MMSE score, and use of multivi-
tamins. Pragmatically, one complex model was created
for all drug groups by using ‘number of ATC-coded
substances used’ as independent variable. Based on lit-
erature, the following variables were considered as ex-
tra, potential confounders: BMI, season, plasma creati-
nine, plasma albumin, MMSE score, education,
smoking, use of alcohol, use of a vitamin D supple-
ment, and use of a multivitamin supplement [18, 19].
Variables were included in the model if they changed
the unstandardised regression coefficient ≥10 % after
being added (linear regression, stepwise method).
To meet the assumption of normal distribution of the
dependent variable and its residuals, square-root transfor-
mation of 25(OH)D was applied. Normality was checked
through histograms, normal Q-Q plots, and detrended Q-
Q plots. Since associations between medication and
square-root transformed 25(OH)D values and differences
in means of such a variable are difficult to interpret, the
adjusted means of transformed 25(OH)D were squared
(back transformation) to calculate the easy to interpret
mean untransformed 25(OH)D levels of users and non-
users of a medication. The difference in adjusted means
25(OH)D between users and non-users of a specific drug
group is equivalent to the regression coefficient beta (β).
This is important to realise as a regression coefficient,
difference, or confidence interval of a square-root trans-
formed variable cannot be squared as back transforma-
tion [20]. The assumption homogeneity of variance was
tested with the Levene’s test. In case of significance, we
double-checked this assumption with the variance ratio
test, as in large groups small differences in variance
may still result in a significant Levene’s test because of
increased power of this test. Effect modification by the
individual covariates was tested by assessment of statis-
tical significance of the interaction terms medication*covariate
for each of the drug groups of interest. In case of significant
interaction (p value<0.1), analyses were stratified. Statistical
tests were two-tailed and, apart from the testing of interaction, a
p value<0.05 was the criterion for statistical significance.
Results
Characteristics
In Table 1 the characteristics of 783 geriatric outpatients
are presented. Median number of medications used was
6 [IQR 3–9], prevalence of polypharmacy 65 %, of
severe polypharmacy 22 %. Depending on the cut-off
value used, prevalence of vitamin D deficiency was
49 % (25(OH)D <50 nmol/l) or 77 % (<75 nmol/l).
Of the 152 patients using a vitamin D supplement, a
considerable number were still deficient: 17 % at
<50 nmol/l and 49 % at <75 nmol/l, respectively and
of the 631 non-users, 57 and 83 %, respectively. In the
severe polypharmacy subgroup of these non-users, prev-
alence of deficiency was 73 and 88 %, respectively.
Compared to the supplement users, the non-users were
younger (≥80 years: 44 % versus 59 %, p< 0.01), had a
lower risk of malnutrition (MNA screening score 12–14:
62 % versus 45 %, p< 0.01), and used fewer medica-
tions (median [IQR]: 5 [3–8] versus 9 [6–12], p< 0.01).
Associations between drug use and vitamin D level
Table 2 shows the associations between drug use and
serum 25(OH)D adjusted for age and gender, in patients
no t us ing a v i t amin D supp lemen t (n = 631) .
Associations are expressed as V-betamedication (β). For
the complete results of the further adjustments in the
complex model we refer to Table 3 in the electronic
supplementary material of the online version of this
article.
The majority of statistical significant associations
were inverse associations. In the simple model, adjusting
for age and gender, we found negative associations for the
number of medications used, polypharmacy, severe
polypharmacy, use of oral antidiabetics, metformin, SUDs,
vitamin K antagonists, cardiac glycosides, loop diuretics in
subjects age≥80 years, potassium-sparing diuretics, ACE in-
hibitors, and the antidepressive SSRIs. By contrast, the asso-
ciation with the antidepressive NSMRIs was positive in
subjects<80 years. The most extreme differences between ad-
justed mean 25(OH)D level of users and non-users of a medi-
cation were −14.5 nmol/l for SUDs and +17.5 nmol/l for
NSMRIs.
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After further adjustment for BMI, MMSE score, and
use of multivitamins, statistical significance of associa-
tions with oral antidiabetics, metformin, and SSRIs dis-
appeared. The inverse association with vitamin K antag-
onists was only borderline significant in subjects with a
BMI ≥27.0 (β=−0.5, p= 0.07). An inverse association
with thiazide diuretics became statistically significant
for subjects with a BMI <21.0 (β=−1.5, p= 0.01), just
as a positive association for angiotensin-2 antagonists in
patients with MMSE scores between 0-24 (β = 0.5,
p = 0.02). The most extreme differences in adjusted
mean 25(OH)D level were −19.3 nmol/l for thiazide
diuretics and +16.8 nmol/l for NSMRIs.
Discussion
Our study population consisted of 783 community-living
older people who visited the geriatric outpatient clinic
for various complaints. In the total population,
polypharmacy and vitamin D deficiency were highly
prevalent. Amongst users of vitamin D supplements,
vitamin D deficiency was still prevalent. In patients
not using supplemental vitamin D, inverse associations
with serum 25(OH) were observed for the number of
medications used, (severe) polypharmacy, antidiabetics,
cardiac glycosides, diuretics, ACE inhibitors, and
SSRIs; positive associations for angiotensin-2 antago-
nists and NSMRIs.
In the following discussion of possible mechanisms
behind observed associations, confounding by indication
should be kept in mind: the entanglement of medication
and indication for its prescription as precipitating
factors.
To start with the inverse associations between the
number of medications used and polypharmacy and vi-
tamin D level, these were also observed in the only
other cross-sectional study investigating these relation-
ships [18]. Such inverse associations were not unexpected,
as polypharmacy is associated with frailty [21], which in turn
is a predictor of low circulating 25(OH)D [22].
A lack of relationship with use of PPIs was con-
firmed by a quasi-experimental study (n= 21) [23] and
a prospective cohort study (n = 58) [24]. A cross-
sectional study (n= 737) detected a borderline signifi-
cant inverse association for which no explanation was
given [18].
The absence of a significant association for osmoti-
cally acting laxatives could not be compared with liter-
ature data as no other publications were identified.
Table 1 Characteristics of a population of 783 Dutch geriatric outpatients, aged 55 years and older
Characteristic Category Percentage or
median [IQR]
Characteristic Category Percentage or
median [IQR]
Gender male 40.1 MMSE (score) 24 [19–27]
female 59.9 0–18 22.1
Age (year) 79 [73–84] 19–24 31.4
≥80 46.9 25–30 46.5
BMI (kg/m2) 26.5 [23.6–29.7] Smoking status never 64.4
<21.0 9.4 former 25.0
21.0–26.9 43.8 current 10.6
≥27.0 46.8 Serum 25(OH)D (nmol/l) 50 [33–72]
MNA screeninga (score) 12 [10–13] <50 49.4
0–7 7.9 50–74 27.1
8-11 33.4 ≥75 23.5
12-14 58.7 Medicationsd (number) 6 [3–9]
Alcohol usec not/light 85.3 use (≥1) 95.1
moderate 12.0 polypharmacy (≥5) 64.9
excessive 2.7 severe polypharmacy (≥10) 21.7
Education level primary school only 39.3 Vitamin D supplement use (≥1) 19.4
ATC anatomic therapeutic chemical classification, BMI body mass index, IQR interquartile range, MMSE mini mental state examination, MNA mini
nutrition assessment, 25(OH)D 25-hydroxyvitamin D
aBetween 1 August 2011–31 December 2013
b In a subpopulation aged ≥65 years, between 21 September 2011–31 December 2013
cAlcohol consumption index according to Garretsen [14]
d All ATC-coded substances (ATC-coded supplements included)
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Table 2 Medicationa use and associated serum 25(OH)D, adjusted for age and genderb, in 631 Dutch geriatric outpatients not using a specific vitamin
D supplement
Medication use Serum 25(OH)D
ATC code Medication Usec No. Meand
25(OH)D
(nmol/l)




Any Number of medications used 631 −0.0f 0.02
Any Polypharmacyg 0 256 48.9 [46.0; 52.0] −0.3 0.06
1 375 45.2 [42.9; 47.7]
Any Severe polypharmacyh
males 0 221 50.7 [47.8; 53.7] −0.7 0.01
1 47 41.0 [35.5; 46.9]
females 0 306 45.3 [42.5; 48.2] −0.1 0.72
1 57 44.0 [37.8; 50.8]
A02BC Proton pump inhibitors 0 398 47.4 [45.1; 49.9] −0.1 0.32
1 233 45.5 [42.5; 48.6]
A06AD Osmotically acting laxatives 0 562 47.1 [45.1; 49.1] −0.3 0.26
1 69 43.7 [38.4; 49.4]
A10B Oral antidiabetics 0 520 47.8 [45.7; 49.9] −0.4 0.02
1 111 41.9 [37.8; 46.2]
A10BA Biguanides (metformin only) 0 541 47.7 [45.7; 49.8] −0.5 0.01
1 90 40.8 [36.3; 45.5]
A10BB Sulfonamides and urea derivatives
males, age < 80 yearsi 0 148 54.9 [51,3; 58,6] −1.1 <0.01
1 20 40.4 [32.4; 49.3]
age ≥ 80 years 0 90 42.6 [38.3; 47.2] −0.2 0.76
1 10 40.4 [28.5; 54.6]
females, age < 80 years 0 167 50.8 [46.8; 55.0] −0.2 0.69
1 19 48.2 [37.2; 60.7]
age ≥ 80 years 0 163 39.1 [35.6; 42.7] 0.7 0.19
1 14 48.0 [35.5; 62.4]
B01AA Vitamin K antagonists 0 551 47.6 [45.6; 49.6] −0.5 0.02
1 80 41.1 [36.3; 46.3]
B01AC Platelet aggregation inhibitors 0 404 46.6 [44.3; 49.0] 0.0 0.88
1 227 46.9 [43.8; 50.1]
C01AA Cardiac glycosides (digoxin only) 0 607 47.1 [45.2; 49.0] −0.7 0.07
1 24 38.2 [29.9; 47.5]
C03AA Thiazide diuretics 0 516 46.8 [44.8; 48.9] 0.0 0.82
1 115 46.3 [42.0; 50.8]
C03CA Loop diuretics
age < 80 years 0 324 52.0 [49.3; 54.8] −0.3 0.45
1 30 48.5 [40.2; 57.5]
age ≥ 80 years 0 217 42.5 [39.6; 45.7] −0.7 0.01
1 60 34.4 [29.4; 39.8]
C03D Potassium-sparing diuretics
males 0 256 49.6 [46.9; 52.3] −1.1 0.02
1 12 35.6 [25.8; 47.1]
females 0 332 45.1 [42.5; 47.9] 0.0 0.98
1 31 45.0 [36.5; 54.3]
C07AB Selective beta-blocking agents 0 441 47.1 [44.8; 49.4] −0.1 0.60
1 190 45.9 [42.6; 49.4]
C08CA Dihydropyridines 0 534 46.7 [44.7; 48.7] 0.0 0.92
1 97 46.9 [42.3; 51.8]
C09AA ACE inhibitors 0 474 47.9 [45.7; 50.1] −0.3 0.04
1 157 43.3 [39.7; 47.0]
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In three cross-sectional studies a negative association
with oral antidiabetics was also observed (n = 737,
n= 407, N= 11256) [18, 25, 26]. At the same time, a
previous quasi-experimental study (n= 19) and a cross-
sectional study (n = 698), did not show these associa-
tions [27, 28]. Obviously, not only medication itself
might be an explanation, but also the indication for its
prescription. This confounding by disease is supported
by a meta-analysis of prospective studies investigating
25(OH)D and type 2 diabetes [29]. Underlying mecha-
nisms might include a decreased insulin sensitivity re-
lated with increased parathyroid hormone levels which,
in turn, are associated with vitamin D deficiency [30].
Another explanation might be vitamin D deficiency be-
ing mediated by inflammatory mediators which are as-
sociated with the presence of excess visceral fat, a risk
factor for diabetes mellitus type-2 [10].
Lower 25(OH)D levels in users of vitamin K antagonists
were also seen in a Dutch cross-sectional study in 514
females;[18] and in a German cross-sectional study in 7553
males [26]. In three other cross-sectional studies (n=116,
n=48, n=127) and one prospective cohort study (n=167),
no associations were observed [31–34].
Associations with platelet aggregation inhibitors were
contradictory in literature. Similar to our study, one
cross-sectional study (n=1301, n=737) did not show an
Table 2 (continued)
Medication use Serum 25(OH)D
ATC code Medication Usec No. Meand
25(OH)D
(nmol/l)




C09CA Angiotensin-2 antagonists 0 524 46.1 [44.1; 48.2] 0.3 0.18
1 107 49.6 [45.0; 54.4]
C10AA Statins 0 451 47.4 [45.2; 49.6] −0.2 0.28
1 180 45.1 [41.7; 48.6]
N02BE Anilides (paracetamol only) 0 538 47.3 [45.3; 49.4] −0.3 0.13
1 93 43.3 [38.7; 48.1]
N05j Benzodiazepines 0 485 46.5 [44.4; 48.7] 0.1 0.73
1 146 47.3 [43.5; 51.4]
N06A Antidepressants
males 0 233 48.6 [45.8; 51.4] 0.2 0.49
1 35 51.4 [44.0; 59.3]
females 0 296 45.8 [43.0; 48.8] −0.3 0.26
1 67 42.1 [36.4; 48.1]
N06AA NSMRIs
age < 80 years 0 333 50.8 [48,2; 53,4] 1.1 <0.00
1 21 68.3 [56.7; 80.9]
age ≥ 80 years 0 254 40.8 [38.1; 43.7] −0.1 0.72
1 23 39.1 [30.5; 48,8]
N06AB SSRIs 0 578 47.4 [45.4; 49.4] −0.6 0.02
1 53 39.8 [34.1; 46.0]
ATC anatomic therapeutic chemical Classification, CI confidence interval, PPIs proton pump inhibitors, NSMRIs non-selective monoamine reuptake
inhibitors, SSRIs selective serotonin reuptake inhibitors, 25(OH)D 25-hydroxyvitamin D
aATC-coded substances
b If interaction with medication: stratification
c 0 = no use, 1 = use
d Squared mean of ‘square-root transformed 25(OH)D’
e Difference in mean ‘square root transformed 25(OH)D’ between users and non-users of a medication (which is equivalent to the regression coefficientβ
of an association between drug use and 'square root transformed 25(OH)D')
f -0.043 = regression coefficient β of the association between the number of medications used and ‘square root transformed 25(OH)D’ (which is
equivalent to the difference in mean ‘square root transformed 25(OH)D’ between users and non-users of a medication)
g Use of ≥5 medications concomitantly
h Use of ≥10 medications concomitantly
i Independent t test because of unequal variances
j N05BA, N05CD or N05CF
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inverse relationship, [18] while three others did (n=11256,
n=2016, n=459) [26, 35, 36]. Confounding by indication
might lie behind the suggestion that elevated inflammatory
markers link hypovitaminosis D with increased risk of
cardiovascular disease [36].
Opposite to our results, an inverse relationship with cardiac
glycosides was not observed in two cross-sectional studies
investigating digoxin (n=1301, n=11256) [18, 26].
Also in other studies observed associations with thiazide
diuretics were mixed. Two cross-sectional studies (n=1301,
n=737; n=66) did not report any significant association [18,
37]. Contrarily, a small randomised placebo-controlled cross-
over trial (n= 23) reported a dose-dependent increase in
25(OH)D levels, [38] while a third cross-sectional study
(n=302) reported an inverse association [39]. This might be
confounded by indication as hypertension is inversely associ-
ated with vitamin D status [40].
Lower 25(OH)D levels amongst users of loop diuretics
were also determined in two cross-sectional studies
(n=1301, n=280), [18, 41] In the first study, results were
significant when adjusted for age and gender; when number
of chronic diseases was added, significance disappeared.
However, in a complex model with six extra covariates the
association was again significant. In two other cross-sectional
studies (n=302, n=77) associations were not statistically sig-
nificant [39, 42].
Our observation of an inverse association with potassium-
sparing diuretics was not supported by one other cross-
sectional study (n=1301) [18]
No association with selective beta-blocking agents was
found in two cohorts of a cross-sectional study (n=1301,
n=737) [18].
Similar to our results, no difference in 25(OH)D levels was
reported in a small cross-sectional study (n=22) investigating
dihydropyridines [43]. This was also the case in two other,
larger cross-sectional studies (n=1301, n=11256) investigat-
ing the broader therapeutic subgroup of calcium blocking
agents [18, 26]. However, in a second cohort of one of these
studies (n=737) a statistically significant inverse association
was identified [18]. It is hypothesised that activation of the
nuclear pregnane X receptor by calcium blockers might lead
to catabolism of 25(OH)D [44].
Lower 25(OH)D levels in users of ACE inhibitors were
also observed in a German and a Dutch cross-sectional study
(n=11256, n=737) [ref 15, 22], while in a second cohort of
the Dutch study (n=1301) [18] and in two quasi-experimental
studies (n=73, n=60) [45, 46] no relationship was shown. A
third quasi-experimental study reported higher levels in users
of quinapril (n= 23) and no change in users of enalapril
(n=23) [47]. It cannot be excluded that an inverse association
reflects the inverse relationship between low 25(OH)D level
and the indication for prescription: high blood pressure29 and
associated comorbidities of diabetes [29].
Our finding of a positive association with angiotensin-2
antagonistswas not detected in two other cross-sectional stud-
ies (n=11256, n=31) [26, 48].
Similar to our study, no association with statinswas detected
in two regression models of a cross-sectional study after multi-
ple adjustments (n=737); in a third model of this study, a bor-
derline significantly inverse association was found after adjust-
ment for age and gender only [18]. In a large cross-sectional and
small cohort study (n=11256, n=208) associations observed
were positive [26, 49]. Studies investigating individual statins
reported null or positive associations [9]. Several mechanisms
are suggested for a positive association: an increase in level of
precursors for vitamin D synthesis in the skin by inhibition of
the HMG-CoA reductase, [50] competition of statins with the
metabolising enzyme CYP3A4, [51], or inhibition by statins of
vitamin D-consuming inflammatory processes [27].
The absence of a significant association with benzodiazepines
was also reported in two other cross-sectional studies (n=737,
n=589) [18, 52]. In a second cohort of the first study, a signifi-
cant inverse association was observed (n=1301) [18].
The finding of an inverse relationship with antidepressants
in one other cross-sectional study (n=589) [52] supports our
finding of lower 25(OH)D levels in users of SSRIs. An inverse
association might be explained by inhibition of 25(OH)D syn-
thesis through inhibition of the CYP3A4 enzyme [53]. The
inverse relationship between depression and 25(OH)D report-
ed in literature [54] does not match with our results for users of
NSMRIs, who had higher 25(OH)D levels compared to non-
users in the complex model.
The finding that a considerable part of the reported users of
vitamin D supplements were still deficient is noteworthy.
Possible explanations could lie in the type and quality of vi-
tamin D supplements, dosing guidelines, duration of use,
compliance, and interindividual differences in pharmacody-
namics and pharmacokinetics in our group of patients, but
these remain to be investigated further.
Major limitation of our study is the cross-sectional design,
which implies that no conclusions can be drawn about causal
relationships. A critical remark has also to be made about our
interpretation of cross-sectional. Laboratory measurements of
25(OH)D were included until four months preceding the first
visit of the outpatient clinic; 95 % of these assays were mea-
sured on the day of first visit. Underlying considerations were
the following. Firstly, the pragmatic reason that physicians did
not request vitamin D testing within four months following a
previous measurement in the hospital. Secondly, the assump-
tion that the investigated drugs were already being used for a
longer period, so also at the moment of a previous vitamin D
assessment. One more critical remark must be made, on the
HPLC assay used for 25(OH)D measurement. This is a less
accurate method compared to the golden standard liquid
chromatography-mass spectrometry. Another limitation of
the study is the registration of the drugs used, which was
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dependent on the cooperation, memory, and assistance of the
patients or their accompanying persons, and the accurateness
of drug registration by pharmacies. Furthermore, although pa-
tients were also routinely asked for drug therapy compliance,
no drug analysis was undertaken to confirm their response or
that of their helper. This, combined with the fact that registra-
tion in the patient files was not standardised, was reason not to
include compliance as a potential covariate. Uncertainty about
drug compliance also influences the effect of use of a vitamin
D supplement. Long-term formulations could be an option to
improve this. Also important to mention is that we did not
adjust for confounding by indication. Reasons were the com-
plexity of this confounder and lacking data. Finally, we note
that one or more of the statistically significant results may be
regarded as chance findings. The large number of medication
groups increases the possibility of false-positive results.
Despite these reservations, our study has several notewor-
thy strengths. It adds to the data of the relatively unexplored
field of drug-nutrient interactions and reflects the typical pop-
ulation of community-dwelling older people visiting a non-
academic regional hospital. That we investigated a large num-
ber of drug groups which are frequently used by older people
further contributes to the quality of the study. Finally, the
ATC-coding is a major strength; it enabled us to investigate
drug and supplement use in a systematic way.Moreover, as far
as we know, in studies investigating drug use and circulating
25(OH)D, we are the first to discriminate between users and
non-users of supplemental vitamin D.
Conclusion
Drug use should be recognised as a determinant of vitamin D
status. The still high prevalence of vitamin D deficiency in
subjects using a vitamin D supplement requires further
investigation.
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